<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058131</url>
  </required_header>
  <id_info>
    <org_study_id>MC-DF</org_study_id>
    <nct_id>NCT05058131</nct_id>
  </id_info>
  <brief_title>Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre</brief_title>
  <official_title>The Effects of Fermentable Dietary Fibre Supplementation on Intestinal Permeability and Inflammation in Microscopic Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines how a fermentable dietary fibre known to promote butyrate production&#xD;
      impacts intestinal barrier function, intestinal microbiota, intestinal inflammation, and&#xD;
      gastrointestinal symptoms in patients with microscopic colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study examines the effects of a 6-week supplementation period with a dietary fibre&#xD;
      product (type of wheat bran) on intestinal barrier function, intestinal inflammation,&#xD;
      intestinal microbiota, and gastrointestinal symptoms in patients with MC. The study subjects&#xD;
      will consume the study products (placebo-fibre, butyrate-promoting fibre) as a powder&#xD;
      supplemented to their daily habitual diet. A maltodextrin-based product is used as placebo.&#xD;
      After giving their informed consent, the study subjects fill out a background questionnaire&#xD;
      to assess their eligibility for the study (Visit 1). Participants deemed suitable for the&#xD;
      study will be randomised into two study arms (placebo-fibre, butyrate-promoting fibre) before&#xD;
      undergoing a baseline visit (Visit 2) before the start of the intervention period. After the&#xD;
      6-week intervention period, the participants will come back for a final visit (Visit 3). In&#xD;
      vivo intestinal permeability will be measured using the standard multi-sugar test at visits 2&#xD;
      and 3. Blood and faecal samples will also be collected during visits 2 and 3. In addition to&#xD;
      the visits described above, a subset of patients (max. 20) will undergo a colonoscopy before&#xD;
      and at the end of the intervention period at Örebro University Hospital where an experienced&#xD;
      gastroenterologist collects 16 colonic biopsies. These colonic biopsies are mounted in an&#xD;
      Ussing chamber system to specifically study colonic permeability. During visits 2 and 3, the&#xD;
      participants also complete questionnaires to assess their gastrointestinal symptoms, quality&#xD;
      of life, physical activity, and dietary habits. During the study period, the participants&#xD;
      will also keep a daily diary recording the number of diarrheal and loose stools. The&#xD;
      participants are asked to maintain their habitual diet and lifestyle as well as not to&#xD;
      consume probiotic or prebiotic supplements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic permeability in vivo</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in urinary sucralose/erythritol excretion ratio between the study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Small intestinal permeability in vivo</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in urinary lactulose/rhamnose excretion ratio between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic permeability ex vivo in Ussing chambers</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the translocation of FITC-labeled dextran and horseradish peroxidase between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of intestinal fatty-acid binding protein</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in plasma concentrations of intestinal fatty-acid binding protein between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of lipopolysaccharide-binding protein</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in plasma levels of lipopolysaccharide-binding protein between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentratios of faecal calprotectin</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in faecal levels of calprotectin between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of faecal myeloperoxidase</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in faecal levels of myeloperoxidase between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of high-sensitive C-reactive protein</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in plasma levels of high-sensitive C-reactive protein between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of inflammatory cytokines</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in TNF-a, IFN-y, IL-1B, IL-4, IL-6, IL-8, IL-10 levels in serum between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of intestinal microbiota</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the composition of intestinal microbiota between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality of intestinal microbiota</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the levels of intestinal microbiota -derived metabolites in the serum and faeces between the study arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Faecal output measured by a daily diary</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the number of diarrhoeal stools per day between the study arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal symptoms measured by Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the frequency and severity of gastrointestinal symptoms between the study arms (15 questions with a scale of 1-7, minimum value 1, maximum 7, higher score correspond to a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life measured by EQ-5D-5L questionnaire</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the scores of the quality of life between the study arms (Visual Analog Scale 0-100, lower value corresponds to a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety and depression measured by Hospital Anxiety and Depression Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the scores of anxiety and depression between the study arms (depression and anxiety scores separately, 7 questions each with a scale of 0-3, minimum score 0, maximum score 21 in both, higher value corresponds to a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>General well-being measured by Short Health Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the scores of general well-being between the study arms (4 questions with a scale of 1-7, higher scores correspond to a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentrations of systemic and faecal markers of oxidative stress</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in blood and faecal markers of oxidative stress (e.g. glutathione) between the study arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentrations of faecal chromogranins</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in faecal levels of chromogranins between the study arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Microscopic Colitis</condition>
  <arm_group>
    <arm_group_label>Dietary fibre</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Butyrate-promoting dietary fibre</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo compound</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo compound</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary fibre</intervention_name>
    <description>Dietary fibre as a powder, 24 g per day for 6 weeks</description>
    <arm_group_label>Dietary fibre</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo compound</intervention_name>
    <description>Maltodextrin powder, 24 g per day for 6 weeks</description>
    <arm_group_label>Placebo compound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Diagnosis of microscopic colitis (collagenous or lymphocytic colitis)&#xD;
&#xD;
          3. Active disease with no medication (e.g. budesonide) or stable budesonide treatment&#xD;
             with or without symptoms&#xD;
&#xD;
          4. Age between 18-75&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous diagnosis of other organic gastrointestinal disease that interferes with the&#xD;
             outcome parameters used in this study (e.g. ulcerative colitis)&#xD;
&#xD;
          2. Previous abdominal surgery which might influence gastrointestinal function, except&#xD;
             appendectomy and cholecystectomy&#xD;
&#xD;
          3. History of or present gastrointestinal malignancy or polyposis&#xD;
&#xD;
          4. Diagnosis of gastrointestinal infection within the last 6 months&#xD;
&#xD;
          5. Current diagnosis of dementia, severe depression, major psychiatric disorder, or other&#xD;
             incapacity for adequate cooperation&#xD;
&#xD;
          6. Chronic neurological/neurodegenerative disease (e.g. Parkinson's disease)&#xD;
&#xD;
          7. Autoimmune disease (e.g. rheumatoid arthritis)&#xD;
&#xD;
          8. Chronic pain syndromes (e.g. fibromyalgia)&#xD;
&#xD;
          9. Chronic fatigue syndrome&#xD;
&#xD;
         10. Severe endometriosis&#xD;
&#xD;
         11. Coeliac disease&#xD;
&#xD;
         12. Diagnosis of lactose intolerance within the last 3 months&#xD;
&#xD;
         13. Pregnancy or breast-feeding&#xD;
&#xD;
         14. Regular intake of anti-inflammatory and/or other immunosuppressive medication than&#xD;
             budesonide within the last 3 months&#xD;
&#xD;
         15. Intake of proton pump inhibitors (e.g. omeprazol) within the last 4 weeks&#xD;
&#xD;
         16. Use of anti-depressants within the last 3 months&#xD;
&#xD;
         17. Regular intake of mast cell stabilizing drugs (e.g. sodium cromoglycate) within the&#xD;
             last 3 months&#xD;
&#xD;
         18. Antimicrobial treatment within the last 12 weeks before baseline sampling&#xD;
&#xD;
         19. Antimicrobial prophylaxis (e.g. urinary tract infection)&#xD;
&#xD;
         20. Regular intake of probiotics, nutritional supplements, or herb products that might&#xD;
             affect intestinal function within the last 4 weeks if the investigator considers that&#xD;
             those could affect study outcome&#xD;
&#xD;
         21. Inability to maintain current diet and lifestyle during the study period&#xD;
&#xD;
         22. Alcohol or drug abuse&#xD;
&#xD;
         23. Any clinically significant present or past disease/condition which the investigator&#xD;
             considers to possibly interfere with the study outcome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Brummer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard A Forsgård, PhD</last_name>
    <phone>0790614037</phone>
    <phone_ext>+46</phone_ext>
    <email>richard.forsgard@oru.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Örebro University</name>
      <address>
        <city>Örebro</city>
        <state>Örebro Län</state>
        <zip>703 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard A Forsgård, PhD</last_name>
      <phone>0790614037</phone>
      <phone_ext>+46</phone_ext>
      <email>richard.forsgard@oru.se</email>
    </contact>
    <investigator>
      <last_name>Robert J Brummer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Microscopic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

